Influence of ezetimibe on ADMA-DDAH-NO pathway in rat liver subjected to partial ischemia followed by global reperfusion

Pharmacological Reports

Volumn 65, Issue 1, 2013, Pages 122-133

  Trocha, Małgorzata ^a   Merwid La̧d, Anna ^a   Sozański, Tomasz ^a   Chlebda Sieragowska, Ewa ^a   Szuba, Andrzej ^a   Dziȩgiel, Piotr ^a,b,c   Pieoeniewska, Małgorzata ^a   Fereniec Gołȩbiewska, Lidia ^a   Kwiatkowska, Joanna ^a   Gomułkiewicz, Agnieszka ^a   Cwynar Zaja̧c, Łucja ^a   Brykner, Renata ^a   Szela̧g, Adam ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c UNIVERSITY SCHOOL OF PHYSICAL EDUCATION   (Poland)

Author keywords

ADMA; ENOS; Ezetimibe; Ischemia reperfusion; Liver; Rat

Indexed keywords

6 N,N' DIMETHYLARGININE; ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ARGININE; ASPARTATE AMINOTRANSFERASE; DIMETHYLARGININASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EZETIMIBE; HEPARIN; KETAMINE; MEDETOMIDINE; PLACEBO; PROTEIN ARGININE METHYLTRANSFERASE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; LIVER HOMOGENATE; LIVER INJURY; MALE; NONHUMAN; RAT; REAL TIME POLYMERASE CHAIN REACTION; REPERFUSION INJURY;

EID: 84875769868     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(13)70970-8     Document Type: Article

References (50)

1. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP: Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation, 1998, 98, 1842-1847.
2. Bulut D, Hanefeld C, Bulut-Streich N, Graf C, Mugge A, Spiecker M: Endothelial function in the forearm circulation of patients with the metabolic syndrome - effect of different lipid-lowering regimens. Cardiology, 2005, 104, 176-180.
3. Cardounel AJ, Cui H, Samouilov A, Johnson W, Kearns P, Tsai AL, Berka V, Zweier JL: Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem, 2007, 282, 879-887.
4. Chobanyan K, Thum T, Suchy MT, Zhu B, Mitschke A, Gutzki FM, Beckmann B et al.: GC-MS assay for hepatic DDAH activity in diabetic and non-diabetic rats by measuring dimethylamine (DMA) formed from asymmetric dimethylarginine (ADMA): evaluation of the importance of S-nitrosothiols as inhibitors of DDAH activity in vitro and in vivo in humans. J Chromatogr B Analyt Technol Biomed Life Sci, 2007, 858, 32-41.
5. Dice JF, Walker CD: Protein degradation in metabolic and nutritional disorders. Ciba Found Symp, 1979, 75, 331-350.
6. Dimitrow PP, Undas A, Bober M, Tracz W, Dubiel JS: Plasma biomarkers of endothelial dysfunction in patients with hypertrophic cardiomyopathy. Pharmacol Rep, 2007, 59, 715-720.
7. Fan C, Zwacka RM, Engelhardt JF: Therapeutic approaches for ischemia/reperfusion injury in the liver. J Mol Med, 1999, 77, 577-596.
8. Fukuda M, Nakamura T, Kataoka K, Nako H, Tokutomi Y, Dong YF, Yasuda O et al.: Ezetimibe ameliorates cardiovascular complications and hepatic steatosis in obese and type 2 diabetic db/db mice. J Pharmacol Exp Ther, 2010, 335, 70-75.
9. Furchgott RF. The 1996 Albert Lasker Medical Research Awards. The discovery of endothelium-derived relaxing factor and its importance in the identification of nitric oxide. JAMA, 1996, 276, 1186-1188.
10. Garcia-Cavlo M, Lisnock JM, Bull HG, Hawes BE, Burnett DA, Braun MP, Crona JH et al.: The target of ezetimibe is Niemann-Pick C 1-Like 1 (NPC1L1). Proc Natl Acad Sci USA, 2005, 102, 8132-8137.
11. Hines IN, Harada H, Flores S, Gao B, McCord JM, Grisham MB: Endothelial nitric oxide synthase protects the post-ischemic liver: potential interactions with superoxide. Biomed Pharmacother, 2005, 59, 183-189.
12. Hornig B, Arakawa N, Böger RH, Bode-Böger SM, Frölich JC, Drexler H: Plasma levels of ADMA are increased and inversely related to endothelium-mediated vasodilation in patients with chronic heart failure: a new predictor of endothelial dysfunction? Circulation, 1998, 98, Suppl I, 318.
13. Jehlicka P, Stozický F, Mayer O Jr, Varvarovská J, Racek J, Trefil L, Siala K: Asymmetric dimethylarginine and the effect of folate substitution in children with familial hypercholesterolemia and diabetes mellitus type 1. Physiol Res, 2009, 58, 179-184.
14. Laleman W, Omasta A, Van de Casteele M, Zeegers M, Vander Elst I, Van Landeghem L, Severi T et al.: A role for asymmetric dimethylarginine in the pathophysiology of portal hypertension in rats with biliary cirrhosis. Hepatology, 2005, 42, 1382-1390.
15. Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S, Manes C et al.: Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation, 2005, 111, 2356-2363.
16. Leiper J, Murray-Rust J, McDonald N, Vallance P: S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci USA, 2002, 99, 13527-13532.
17. Leiper J, Santa Maria J, Chubb A, MacAllister RJ, Charles IG, Whitley GS, Vallance P: Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J, 1999, 343, 209-214.
18. Leiper J, Vallance P: Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res, 1999, 43, 542-548.
19. Lhuillier F, Parmantier P, Goudable J, Crova P, Delafosse B, Annat G, Cespuglio R, Viale JP: Hepatic ischemia is associated with an increase in liver parenchyma nitric oxide that is in part enzyme-independent. Anesthesiology, 2003, 98, 373-378.
20. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, Tsuji H et al.: Impaired nitric oxide sythase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation, 2002, 106, 987-992.
21. Lluch P, Torondel B, Medina P, Segarra G, Del Olmo JA, Serra MA, Rodrigo JM: Plasma concentrations of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosis. J Hepatol, 2004, 41, 55-59.
22. Maas R: Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA). Vasc Med, 2005, 10, Suppl 1, S49-S57.
23. Martin-Sanz P, Olmedilla L, Dulin E, Casado M, Callejas NA, Pérez-Peña J, Garutti I et al.: Presence of methylated arginine derivatives in orthotopic human liver transplantation: relevance for liver function. Liver Transpl, 2003, 9, 40-48.
24. Matsuguma K, Ueda S, Yamagishi S, Matsumoto Y, Kaneyuki U, Shibata R, Fujimura T et al.: Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. J Am Soc Nephrol, 2006, 17, 2176-2183.
25. Miranda LE, Capellini VK, Reis GS, Celotto AC, Carlotti CG Jr, Evora PR: Effects of partial liver ischemia followed by global liver reperfusion on the remote tissue expression of nitric oxide synthase: lungs and kidneys. Transplant Proc, 2010, 42, 1557-1562.
26. Mishima T, Hamada T, Ui-Tei K, Takahashi F, Miyata Y, Imaki J, Suzuki H, Yamashita K: Expression of DDAH1 in chick and rat embryos. Brain Res Dev Brain Res, 2004, 148, 223-232.
27. Mookerjee RP, Davies NA, Sen S, Hodges SJ, Turner C, Dalton RN, Williams R, Jalan R: Decreased hepatic extraction of asymmetric and symmetric dimethylarginine (ADMA/SDMA-NOS inhibitors) in acute alcoholic hepatitis may contribute to impaired end-organ function. Hepatology, 2005, 42, 419A.
28. Morales AI, Vicente-Sanchez C, Jerkic M, Santiago JM, Sanchez-Gonzalez PD, Perez-Barriocanal F, Lopez-Novoa JM: Effect of quercetin on metallothionein, nitric oxide synthase and cyclooxygenase-2 expression on experimental chronic cadmium nephrotoxicity in rats. Toxicol Appl Pharmacol, 2006, 210, 128-135.
29. Nakagami H, Osako MK, Takami Y, Hanayama R, Koriyama H, Mori M, Hayashi H et al.: Vascular protective effects of ezetimibe in ApoE-deficient mice. Atherosclerosis, 2009, 203, 51-58.
30. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Ueda Y, Suzuki T, Ueda S et al.: Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner. Pharmacol Res, 2009, 60, 525-528.
31. Nijveldt RJ, Teerlink T, Siroen MP, van Lambalgen AA, Rauwerda JA, van Leeuwen PA: The liver is an important organ in the metabolism of asymmetrical dimethylarginine (ADMA). Clin Nutr, 2003, 22, 17-22.
32. Parker RA, Huang Q, Tesfamariam B: Influence of 3-hydroxy-3- methylglutaryl-CoA (HMG-CoA) reductase inhibitors on endothelial nitric oxide synthase and the formation of oxidants in the vasculature. Atherosclerosis, 2003, 169, 19-29.
33. Peralta C, Rull R, Rimola A, Deulofeu R, Roselló- Catafau J, Gelpí E, Rodés J: Endogenous nitric oxide and exogenous nitric oxide supplementation in hepatic ischemia-reperfusion injury in the rat. Transplantation, 2001, 71, 529-536.
34. Perez MJ, Macias RI, Duran C, Monte MJ, Gonzalez-Buitrago JM, Marin JJ: Oxidative stress and apoptosis in fetal rat liver induced by maternal cholestasis. Protective effect of ursodeoxycholic acid. J Hepatol, 2005, 43, 324-332.
35. Scalera F, Borlak J, Beckmann B, Martens-Lobenhoffer J, Thum T, Tager M, Bode-Boger SM: Endogenous nitric oxide synthesis inhibitor asymmetric dimethyl L-arginine accelerates endothelial cell senescence. Arterioscler Thromb Vasc Biol, 2004, 24, 1816-1822.
36. Schemmer P, Connor HD, Arteel GE, Raleigh JA, Bunzendahl H, Mason RP, Thurman RG: Reperfusion injury in livers due to gentle in situ organ manipulation during harvest involves hypoxia and free radicals. J Pharmacol Exp Ther, 1999, 290, 235-240.
37. Shah V, Haddad FG, Garcia-Cardena G, Frangos JA, Mennone A, Groszmann RJ, Sessa WC: Liver sinusoidal endothelial cells are responsible for nitric oxide modulation of resistance in the hepatic sinusoids. J Clin Invest, 1997, 100, 2923-2930.
38. Shah V, Toruner M, Haddad F, Cadelina G, Papapetropoulos A, Choo K, Sessa WC, Groszmann RJ: Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology, 1999, 117, 1222-1228.
39. Stuhlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP: Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation, 2001, 104, 2569-2575.
40. Sudhop T, von Bergmann K: Cholesterol absorption inhibitors for the treatment of hypercholesterolemia. Drugs, 2002, 62, 2333-2347.
41. Suchy D, Łabuzek K, Stadnicki A, Okopień B: Ezetimibe - a new approach in hypercholesterolemia management. Pharmacol Rep, 2011, 63, 1335-1348.
42. Sydow K, Münzel T: ADMA and oxidative stress. Atheroscler Suppl, 2003, 4, 41-51.
43. Tran CT, Leiper JM, Vallance P: The DDAH/ADMA/NOS pathway. Atheroscler Suppl, 2003, 4, 33-40.
44. Trocha M, Merwid-La̧d A, Szuba A, Chlebda E, Pieoeniewska M, Sozański T, Szela̧g A: Effect of simvastatin on nitric oxide synthases (eNOS, iNOS) and arginine and its derivatives (ADMA, SDMA) in ischemia/reperfusion injury in rat liver. Pharmacol Rep, 2010, 62, 343-351.
45. Trocha M, Merwid-La̧d A, Szuba A, Sozański T, Magdalan J, Szela̧g A: Asymmetric dimethylarginine synthesis and degradation under physiological and pathological conditions. Adv Clin Exp Med, 2010, 19, 223-243.
46. Ueda S, Kato S, Matsuoka H, Kimoto M, Okuda S, Morimatsu M, Imaizumi T: Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: role of dimethylarginine dimethylaminohydrolase. Circ Res, 2003, 92, 226-233.
47. Vallance P, Leiper J: Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol, 2004, 24, 1023-1030.
48. Van de Casteele M, Omasta A, Janssens S, Roskams T, Desmet V, Nevens F, Fevery J: In vivo gene transfer of endothelial nitric oxide synthase decreases portal pressure in anaesthetised carbon tetrachloride cirrhotic rats. Gut, 2002, 51, 440-445.
49. Xiong Y, Fu YF, Fu SH, Zhou HH: Elevated levels of the serum endogenous inhibitor of nitric oxide synthase and metabolic control in rats with streptozotocin-induced diabetes. J Cardiovasc Pharmacol, 2003, 42, 191-196.
50. Xue F, Zhang JJ, Xu LM, Zhang C, Xia Q: Protective effects of HGF-MSP chimer (metron factor-1) on liver ischemia-reperfusion injury in rat model. J Dig Dis, 2010, 11, 299-305.